Skip to main content
Clinical Trials/IRCT20230307057648N1
IRCT20230307057648N1Not yet recruitingPhase 3

Evaluation of the effect of traditional Persian diabetes product (Tabashir tablet) on blood glucose level in patients with type 2 diabetes: a double-blind placebo-controlled clinical trial

Tehran University of Medical Sciences0 sites106 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Enrollment
106

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
30 years to 65 years (—)
Sex
All

Inclusion Criteria

  • •Uncontrolled type 2 diabetes
  • •Age 30-65 years
  • •HbA1c greater than 7 and lower than 8.5
  • •Under treatment with oral diabetes medications (one or more drug groups)
  • •At least one month after increasing the dose of antidiabetic medicine or prescribing a new antidiabetic medicine

Exclusion Criteria

  • •Glomerular filtration rate, lower than 60 ml per minute
  • •Serum albumin, lower than 4 g/dL
  • •SGOT and SGPT, three times higher than normal level
  • •Pregnancy and breastfeeding or intention to become pregnant
  • •Taking insulin along with oral diabetes medications

Investigators

Similar Trials

Effect of Tabashir tablet in treatment of... | Clinical Trial